Consensus Personalis, Inc.

Stocks

PSNL

US71535D1063

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-24 EDT			5-day change	1st Jan Change
16.57 ^USD	+1.35%		+2.09%	+108.17%

08-24	Personalis Shares Fall After Craig-Hallum Downgrade	MT
08-24	Craig-Hallum Downgrades Personalis to Hold From Buy, Price Target is $16.25	MT

Evolution of the Average Target: Personalis, Inc.

Evolution of the Target Price: Personalis, Inc.

Changes in Analyst Recommendations: Personalis, Inc.

422ae33b3042d6e748cc.k_t9eSKPeF6XC-ksJq4Sfu5h-wyRTYqLjcfJlcEt9yM.3bpNTnjALBndMp8fZehaEbwxnzz2PNDu5v-GoY1Eh3bctkVUVMUwGv5Kng~39da1ffa0cab724bc5085531411e8dde

Analysts' recommendations: Personalis, Inc.

08-24	Personalis Shares Fall After Craig-Hallum Downgrade	MT
08-24	Craig-Hallum Downgrades Personalis to Hold From Buy, Price Target is $16.25	MT
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Top Midday Decliners	MT
07-20	Needham Downgrades Personalis to Hold From Buy	MT
07-17	Needham Raises Price Target on Personalis to $17 From $12, Keeps Buy Rating	MT
05-12	Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating	MT
12-02	Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating	MT
25-08-05	Healthcare firm Personalis' Q2 revenue misses estimates	RE
25-05-15	Guggenheim Initiates Personalis at Buy With $6 Price Target	MT
25-03-17	Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target	MT
24-08-16	BTIG Raises Personalis' Price Target to $7 From $5.50, Buy Rating Maintained	MT
24-08-08	Needham Adjusts Personalis' PT to $5.50 From $3.50, Keeps Buy Rating	MT
24-04-30	Lake Street Starts Personalis With Buy Rating, $4 Price Target	MT
24-02-29	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT
23-11-08	Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	MT
23-08-09	HC Wainwright Adjusts Price Target on Personalis to $7.50 From $10, Maintains Buy Rating	MT
23-05-04	Needham Trims Price Target on Personalis to $7 From $8, Maintains Buy Rating	MT
23-02-27	Morgan Stanley Adjusts Price Target on Personalis to $5 From $11, Maintains Equal-Weight Rating	MT
23-02-24	HC Wainwright Trims Price Target on Personalis to $10 From $13, Maintains Buy Rating	MT
23-02-06	Needham Upgrades Personalis to Buy From Hold, Says Encouraged by Cost Reductions, Price Target is $8	MT
22-11-03	HC Wainwright Adjusts Personalis' Price Target to $13 From $26, Keeps Buy Rating	MT
22-11-03	Citigroup Adjusts Price Target on Personalis to $6 From $8, Maintains Buy Rating	MT
22-08-04	Citigroup Lowers Personalis' Price Target to $8 From $14, Maintains Buy Rating	MT
22-08-04	HC Wainwright Adjusts Personalis' Price Target to $26 From $30, Reiterates Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSONALIS, INC.					-5.58%
	LONZA GROUP AG					+22.49%
	IQVIA HOLDINGS INC.					+3.76%
	BEONE MEDICINES AG					+18.58%
	REVOLUTION MEDICINES, INC.					+32.8%
	CELLTRION, INC.					+50.95%
	MEDPACE HOLDINGS, INC.					-5.72%
	EUROFINS SCIENTIFIC SE					-5.14%
	ASCENDIS PHARMA A/S					+39.89%
	TEMPUS AI, INC.					-10.49%
	Average					+14.15%
	Weighted average by Cap.					+19.21%